Head-to-head · free
Alnylam Pharmaceuticals vs Alibaba Group Holding Limited
ALNY vs BABA — return on capital, cash generation, margins and balance sheet side by side.
ALNY
8 / 10
measures where ALNY leads
BABA
2 / 10
measures where BABA leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | ALNY · FY2025 | BABA · FY2026 |
|---|---|---|
| Revenue | $3.7B | $1.02T |
| Net income | (18.3M) | $103.6B |
| Revenue growth (yearly, multi-year) | 44.8% | 4.7% |
| Free cash flow | $465.4M | (50.7B) |
| Free cash flow margin | 12.5% | -5.0% |
| Net cash / (debt) | — | (86.1B) |
| ROIC | 28.4% | 2.8% |
| Return on equity | 73.3% | 10.0% |
| Gross margin | 81.6% | 39.8% |
| Operating margin | 13.5% | 5.8% |
| Net debt / EBITDA | -1.17x | 1.32x |
Figures are as reported by each company; latest fiscal year shown.
Where Alnylam Pharmaceuticals's cash went (FY2025)
- Capital spending
- $58.7M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Alibaba Group Holding Limited's cash went (FY2026)
- Capital spending
- $126.9B
- Buybacks
- $7.6B
- Dividends
- $33.7B
- Acquisitions
- $12.1B
- Net debt issued / (repaid)
- $39.0B
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free